MedPath

AbbVie, Inc.

AbbVie, Inc. logo
🇺🇸United States
Ownership
Public
Established
2013-01-01
Employees
50K
Market Cap
-
Website
http://www.abbvie.com

Clinical Trials

4

Active:4
Completed:0

Trial Phases

1 Phases

Phase 1:3

Drug Approvals

13

SFDA:12
NMPA:1

Drug Approvals

Lopinavir/Ritonavir Oral Solution

Product Name
克力芝
Approval Number
国药准字HJ20130773
Approval Date
Jun 7, 2023
NMPA

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (100.0%)
No trials found

News

Delhi High Court Upholds Strict Patent Amendment Rules in Two Key Pharmaceutical Cases

The Delhi High Court upheld patent rejections in two separate pharmaceutical cases, reinforcing strict disclosure requirements and amendment limitations under Indian patent law.

Global Cerebral Palsy Clinical Trial Landscape Assessed in New 2024 Review

A new report provides an overview of the global clinical trial landscape for cerebral palsy, including trial numbers and enrollment trends.

Cerevel Therapeutics Advances Emraclidine Development for Alzheimer's-Related Dementia and Psychosis

Cerevel Therapeutics is developing Emraclidine (CVL-231), a novel oral M4 muscarinic receptor positive allosteric modulator, for treating dementia and psychosis in Alzheimer's disease.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.